Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The clinical research mission of the Adult Leukemia Program is to develop and bring new and better therapies to patients. At any given time, the program offers patients a wide array of opportunities to participate in clinical research studies relating to all stages and types of leukemia and related disorders. Patients have access to trials that originate within Dana-Farber/Brigham and Women's Cancer Center and other Harvard-affiliated institutions, those sponsored by private industry, as well as those that are part of a collaborative effort, such as the Cancer and Leukemia Group B, of which the program is a member.
The clinical research mission of the Adult Leukemia Program is to develop and bring new and better therapies to patients. At any given time, the program offers patients a wide array of opportunities to participate in clinical research studies relating to all stages and types of leukemia and related disorders.
Patients have access to trials that originate within Dana-Farber/Brigham and Women's Cancer Center and other Harvard-affiliated institutions, those sponsored by private industry, as well as those that are part of a collaborative effort, such as the Cancer and Leukemia Group B, of which the program is a member.
Physician-researchers within the program are currently involved in a number of exciting avenues of investigation, which include targeted therapies aimed at making cancer treatment more specific and less toxic. These include:
Other innovative offerings include treating adults with acute lymphoblastic leukemia by applying the principles used in successful pediatric treatments of this condition and clinical trials and treatments specialized for older adults.
Trial 18-351: A phase 1b study of venetoclax in combination with intensive induction and consolidation chemotherapy in treatment-naïve patients with acute myelogenous leukemiaPrincipal Investigator: Richard Stone, MD
Trial 18-170: A phase 1 study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCRABL+) B-cell acute lymphoblastic leukemia and chronic myeloid leukemia Principal Investigator: Marlise Luskin, MD, MSCE
Trial 17-718: A phase 1 study of ipilimumab in combination with decitabine in relapsed or refractory myelodysplastic syndromes/acute myeloid leukemia Principal Investigator: Jacqueline Garcia, MD
Trial 17-717: A phase 3 trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly-diagnosed precursor B-cell ALL Principal Investigator: Daniel DeAngelo, MD, PhD
Trial 17-056: A phase 1 study of SL-401 in combination with azacitidine and venetoclax in relapsed/refractory acute myeloid leukemia (AML), in treatment-naive patients with AML not eligible for standard induction, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), or SL-401 in combination with azacitidine in patients with high-risk myelodysplastic syndromes Principal Investigator: Andrew Lane, MD, PhD
New Patient Appointments 877-442-3324
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)